DAT antagonists(Dopamine transporter antagonists), PET imaging(Positron-emission tomography enhancers), SPECT(Single-photon emission-computed tomography enhancers)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication

Parkinson Disease

Inactive Indication

Attention Deficit Disorder With HyperactivityDementiaTremor

Originator Organization

Harvard University

Active Organization

Harvard University

Alseres Pharmaceuticals, Inc.

Inactive Organization

Navidea Biopharmaceuticals, Inc.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure

Molecular FormulaC18H21FINO2

InChIKeyGTQLIPQFXVKRKJ-UNSMHXHVSA-N

CAS Registry180468-34-2

Clinical Trials associated with Altropane

NCT06225063 / RecruitingNot ApplicableIIT

The Comparison of Pilates With Cognitive Functional Therapy in Adults With Chronic Neck Pain: A Randomized Controlled Trial

The aim of this study is to compare the effectiveness of Pilates compared with Cognitive Functional Therapy in adults with chronic neck pain.

Start Date15 Aug 2023

Sponsor / Collaborator

European University Cyprus Ltd.

NCT05636852 / RecruitingPhase 2

An Open-label Multicenter Phase 2 Dose-evaluation Study of Altropane (123I) Injection for Striatal Dopamine Transporter Visualization Using SPECT Brain Imaging

Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study will determine if a lower dose (5 millicuries) would suffice.

Start Date24 Apr 2023

Sponsor / Collaborator

GE Healthcare Holdings, Inc.

[+1]

NCT01950468 / WithdrawnPhase 3

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

This is a phase 3, open-label, multiple-center, randomized cross-over study to assess the safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.

Start Date01 Apr 2017

Sponsor / Collaborator

Navidea Biopharmaceuticals, Inc.

100 Clinical Results associated with Altropane

100 Translational Medicine associated with Altropane

100 Patents (Medical) associated with Altropane

146

Literatures (Medical) associated with Altropane

14 Dec 2023·Antimicrobial agents and chemotherapy

Unraveling the mechanism of ceftaroline-induced allosteric regulation in penicillin-binding protein 2a: insights for novel antibiotic development against methicillin-resistant Staphylococcus aureus

Article

Author: Wang, Pinkai ; Bao, Yiqiong ; Zhang, Feng ; Guo, Jingjing ; Tong, Henry H Y ; Jiao, Fangfang ; Li, Mengrong ; Zhang, Yan ; Tao, Jun

ABSTRACT:

Methicillin-resistant Staphylococcus aureus (MRSA) acquires high-level resistance against β-lactam antibiotics by expressing penicillin-binding protein 2a (PBP2a). PBP2a is a cell wall-synthesizing protein whose closed active site exhibits a reduced binding affinity toward β-lactam antibiotics. Ceftaroline (CFT), a fifth-generation cephalosporin, can effectively inhibit the PBP2a activity by binding to an allosteric site to trigger the active site opening, allowing a second CFT to access the active site. However, the essential mechanism behind the allosteric behavior of PBP2a remains unclear. Herein, computational simulations are employed to elucidate how CFT allosterically regulates the conformation and dynamics of the active site of PBP2a. While CFT stabilizes the allosteric domain surrounding it, it simultaneously enhances the dynamics of the catalytic domain. Specifically, the study successfully captured the opening process of the active pocket in the allosteric CFT-bound systems and discovered that CFT alters the potential signal-propagating pathways from the allosteric site to the active site. These findings reveal the implied mechanism of the CFT-mediated allostery in PBP2a and provide new insights into dual-site drug design or combination therapy against MRSA targeting PBP2a.

01 Sep 2023·Behavior therapy

Compassion-Focused Therapy to Reduce Body Weight Shame for Individuals With Obesity: A Randomized Controlled Trial

Article

Author: Gilbert, Paul ; Kirby, James N ; Steindl, Stanley R ; Parker, Stacey ; Carter, Alicia

Adults living in larger bodies (Body Mass Index > 30) often experience body weight shame, are highly self-critical, and are at increased risk for anxiety and depression. To date, there have been no RCTs examining the efficacy of Compassion-Focused Therapy (CFT) to help those experiencing body weight shame. The aim of the current study was to investigate the efficacy of CFT as a 12-session group intervention to reduce body weight shame for individuals living in larger bodies. The study used an RCT design with participants randomized to the CFT (n = 28) or waitlist control (n = 27) condition. Participants in both groups were assessed at pre- and postintervention, with the CFT group alone assessed at 3- and 6-month follow-up intervention. Both self-report and a physiological measure of parasympathetic nervous system activity were used (i.e., heart rate variability). Results indicated that CFT had a significant positive impact at postintervention compared to the control group for body weight shame (internal and external), increasing self-compassion, reducing fears of compassion (self, other, and receiving), reducing self-criticism, and reducing external shame. Although there were no significant group effects at postintervention on depression and anxiety, 66% of participants had clinical improvement on depression in the CFT group compared to 8% in the control group at postintervention. CFT did not shift baseline heart rate variability at postintervention. The evidence from this RCT supports CFT as an efficacious intervention to reduce body weight shame for individuals with obesity.

01 Sep 2023·Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Study on the mechanism of stir-fried Fructus Tribuli in enhancing the essential hypertension treatment by an integrated "spectrum-effect relationship-network pharmacology-metabolomics" strategy

Article

Author: Liu, Kunlin ; Wang, Shuyue ; Zhang, Chao ; Han, Bing ; Sheng, Huagang ; Lv, Xiyu ; Guo, Fei ; Sun, Xiaochen ; Li, Jingna ; Wang, Shuai ; Zhang, Wenhuan

Essential hypertension (EH) is a leading cause of cardiovascular morbidity and mortality. Fructus Tribuli (FT), as a traditional medicine, has been frequently used for thousands of years. The crude Fructus Tribuli (CFT), decoction pieces being processed to remove impurities, have been listed as an important medicine for the treatment of hypertension in the elderly. According to the theory of traditional Chinese medicine, the CFT can enhance the EH treatment after being stir-fried into stir-fried Fructus Tribuli (SFT). At present, whether the SFT can enhance the EH treatment and its potential pharmacodynamic substances and mechanism are unknown. In this study, an integrated "spectrum-effect relationship-network pharmacology-metabolomics" strategy was used. Using male spontaneously hypertensive rats as an experimental model, we compared the therapeutic effects of CFT and SFT on EH. Subsequently, to define the pharmacodynamic material basis of SFT in enhancing the EH treatment, the steroidal saponins (main active components of FT) were selected for spectrum-effect relationship analysis. Furthermore, we applied the joint pathway analysis of network pharmacology and metabolomics to explore the underlying mechanism of SFT in enhancing the EH treatment. Results showed that SFT was better than CFT in the EH treatment. The steroidal saponins transformed by stir-frying were the potential pharmacodynamic substances that SFT could enhance the EH treatment. And the mechanism of action might be associated with regulating glycerophospholipid metabolism and arachidonic acid metabolism, especially arachidonic acid metabolism. This study provided a scientific basis for the clinical use of SFT as an important medicine for the EH treatment.

News (Medical) associated with Altropane

27 Mar 2006

·www.biospace.com

Boston Life Sciences To Present At The CIBC World Markets Annual Biotechnology And Specialty Pharmaceuticals Conference

HOPKINTON, Mass., March 28 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. today announced that Kenneth L. Rice, Jr., Chief Financial Officer of Boston Life Sciences, Inc., will be presenting a Company update at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference on Tuesday, April 4 at 9:00am EST. The conference is being held April 4 - 5, 2006 at the Millennium Broadway in New York City. The Boston Life Sciences presentation will be available by webcast. Access to the webcast will be available for 90 days following the presentation within the Investor Relations section of the Boston Life Sciences website at . About Boston Life Sciences, Inc. Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and a Phase II clinical trial for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, a DAT blocker for the treatment of Parkinson's disease and a second generation technetium-based molecular imaging agent for PS and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital of Boston. ALTROPANE is a registered trademark of Boston Life Sciences, Inc. The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future, including the Company's development efforts regarding the Company's ALTROPANE program and the Company's pre-clinical candidates. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on form 10-Q for the quarter ended September 30, 2005, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences, Inc. is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. Contact: Sharon Correia -- 508-497-2360 ext 224 Boston Life Sciences, Inc. scorreia@bostonlifesciences.com Boston Life Sciences, Inc. CONTACT: Sharon Correia of Boston Life Sciences, Inc., +1-508-497-2360ext. 224, scorreia@bostonlifesciences.com Web site:

Collaborate

100 Deals associated with Altropane

External Link

KEGG	Wiki	ATC	Drug Bank
-	Altropane	-	DB04947

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Phase 3	US	Navidea Biopharmaceuticals, Inc.	01 Nov 2013
Parkinsonian Disorders	Phase 3	US	Alseres Pharmaceuticals, Inc.	01 Jul 2010
Tremor	Phase 3	US	Alseres Pharmaceuticals, Inc.	01 Jul 2010
Dementia	Phase 2	US	Alseres Pharmaceuticals, Inc.	19 Oct 2013
Attention Deficit Disorder With Hyperactivity	Phase 2	US	Alseres Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis